Plain-English translation of NCT04997837 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether adding an immunotherapy medication called a (such as Nivolumab, Pembrolizumab, or Toripalimab) along with radiation therapy to standard can help people with advanced stomach cancer live longer after surgery. The trial will compare patients who receive this combination treatment to those who receive alone, measuring how well the treatment works and what side effects occur.
Stomach cancer with extensive lymph node involvement is very serious, and current treatment after surgery ( alone) doesn't work well enough for many patients. Researchers believe that adding this medication to boost the immune system, combined with radiation, may help prevent cancer from coming back and improve survival.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the new treatment group, you will receive intravenous and the immunotherapy medication for 6 weeks, followed by concurrent and radiation therapy to your abdomen, then another 6 weeks of and the medication, and finally maintenance doses of the immunotherapy medication for up to one year total. If assigned to the standard group, you will receive alone for 6 months. Both groups will have regular clinic visits to monitor your health, blood tests, and imaging scans to check for cancer recurrence.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China